Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of natural bioactive and biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1? and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar’s main research objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with natural anti-tumour proteins which specifically target cancer cells.
Dr. Masoud H Manjili is an Assistant Professor of Immunology at the Department of Microbiology Immunology Virginia Commonwealth University School of Medicine and Member of Massey Cancer Center Richmond VA. He conducted his postdoctoral fellowship at Roswell Park Cancer Institute Buffalo NY 1999-2003. He has received a PhD in Immunology from The University of Sydney Australia 1993-1996. He has received a DVM from The University of Tehran Iran 1983-1990. He is serving as a Managing Editor of Frontiers in Bioscience. Research Interest: Tumor Immunology Tumor Immunoediting Cancer Vaccines Adoptive T cell Therapy Myeloid-derived suppressor cells (MDCS) Cancer Stem Cells Graft-versus-host disease (GVHD) Breast Cancer Neuroblastoma
Research Interest: Tumor Immunology Tumor Immunoediting Cancer Vaccines Adoptive T cell Therapy Myeloid-derived suppressor cells (MDCS) Cancer Stem Cells Graft-versus-host disease (GVHD) Breast Cancer Neuroblastoma
Guanglan Zhang is an Assistant Professor and the faculty coordinator of the Health Informatics Program at Computer Science Department, Metropolitan College (MET) at Boston University. She leads the research activities at MET health informatics research lab. She is also an adjunct member of Bioinformatics Core at Cancer Vaccine Center (CVC), Dana-Farber Cancer Institute (DFCI) and Harvard Medical School. During the many years of pursuing research in biomedical and health sciences, Guanglan has authored more than 50 publications and developed more than a dozen online computational systems. Through the development of advanced computational solutions, she contributes to the rapid progress of basic and applied biology and biomedicine.
Dr. Max Cooper, MD is an allergist/immunologist in Atlanta, Georgia. He is currently licensed to practice medicine in Alabama. He is a Professor at Emory University School of Medicine. His laboratory pursues ontogenetic and phylogenetic studies of the adaptive immune system in parallel with the analysis of immunological diseases in humans. Current projects include the role of immunoglobulin and non-immunoglobulin genes in B cell development, and the evolution of adaptive immune systems in vertebrates.
His laboratory pursues ontogenetic and phylogenetic studies of the adaptive immune system in parallel with the analysis of immunological diseases in humans. Current projects include the role of immunoglobulin and non-immunoglobulin genes in B cell development, and the evolution of adaptive immune systems in vertebrates.
Noah Isakov - Short Biography Professor Noah Isakov holds the Joseph H Krupp Chair in Cancer Immunobiology at the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel. He graduated from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK, where he held the Esther Greenberg Honors Chair in Biomedical Research (2003-2004), and the Otago University in Dunedin, New Zealand (2015).
Hammady Al Hilali studied B.Sc in 1987, M.Sc. in 1996, from Baghdad University College of Science, Iraq and pursued Ph.D. in 2006 in Immunology. He has more than thirteen published papers and supervising more than thirteen Master’s and Ph.D. students in Medical Microbiology. He is Member of department of Medical Microbiology, College of Medicine, Al-Qadisiya University. His Research focuses on the immunology of major auto-immune disease, IBD.
Research interest in diagnostic immunology and in individual variation regarding single nucleotide polymorphisms of many immunological factors during the courses of different auto-immune diseases, e.g., type 1 and 2 Diabetes mellitus, Celiac disease, inflammatory bowel disease, Acne vulgaris, and Asthma are among other disease were the subject of more than 25 published researches. Attendee and speaker at 6 international conferences in the field of immunology, a scientific committee member in one of them, more than 15 national conferences as well. Many international workshops, fellowships, and training courses (Iowa state university, USA/ Mahidol university, Thailand, are examples). Member of editorial board in journal of clinical and cellular immunology (USA), and member of many related associations. Consultant at Ad-diwaniah teaching hospital, immunology and virology diagnostic lab.
He is the principal investigator at the Laboratoty of Immunobiology at Federal University of Rio de Janeiro, Associate Professor at Federal University of Rio de Janeiro, and a Senior Research Specialist from the Presidency of the Oswaldo Cruz Foundation-FIOCRUZ where he investigate the immunological mechanisms associated with changes in central and peripheral lymphoid system in infectious diseases, with major focus in Malaria, Leishmaniasis and Chagas Diseases.
Research Specialist from the Presidency of the Oswaldo Cruz Foundation-FIOCRUZ
Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, VA, USA that he founded in 2002. He is an inventor, entrepreneur, professor and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for over two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery and biodefense, FDA regulatory issues, and patent law. Since 1999, he has held various positions at Rensselaer Polytechnic Institute in Troy, NY, where he is currently an adjunct professor of biological sciences and where he received his doctoral degree in three years (biophysics/biochemistry). Since 2004, he has been an adjunct professor of natural and applied sciences at NVCC in Annandale, VA. He is a scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel. He has served as a principal investigator of National Cancer Institute SBIRs and reviewer for both the NIH and NSF. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner for 6 years. He is a life member of Sigma Xi, co-chair of the Nanotech Committee of the American Bar Association and serves on the global advisory council of the World Future Society. He is frequently interviewed by the media and appeared in such publications as Nature, MIT Technology Review, American Chemical Socitye CE&N, Business Review, etc. He has authored over 100 publications, co-edited four texts and serves on the editorial boards of 17 peer-reviewed journals, including serving as a Special Associate Editor of Nanomedicine (Elsevier) and an Editor-in-Chief of the Journal of Interdisciplinary Nanomedicine (Wiley). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the Undersecretary of Commerce, Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).
Since 2002, Dr. Bawa is listed on the official “Roster of Attorneys and Agents” maintained by the US Patent & Trademark Office (PTO) as a registered patent agent in good standing, licensed to practice before the PTO.
Dr. Su's research has received international recognition in understanding molecular regulation of T-cell immune system aging, focusing on the thymic microenvironment, and associated with aging-induced immune-senescence, autoimmune predisposition, and age-related chronic inflammatory diseases. His team has published more than 40 peer reviewed papers, made significant contributions to defining how aged microenvironment (thymic epithelium) affects hematopoietic stem cell regeneration competence. Currently, his team is clarifying the clinical significance about a balance of self-reactive and regulatory T cells, generated in the aged involuted thymus, which profoundly involve age-related chronic inflammatory condition; and his team is also ascertaining a novel role of the central T-cell immune system on tumor chemotherapy.